No recent analyst price targets found for GRNF.
Latest News for GRNF
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVLAYAH for Hunter Syndrome and robust pipeline momentum. Company's DNL593 for FTD-GRN is differentiated by restoring both extracellular and lysosomal PGRN; phase 1/2 data readout expected by end of 2026. AVLAYAH's full approval depends on confirmatory COMPASS study results; commercial performance remains unproven…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GRNF.
Senate Trading
No Senate trades found for GRNF.
U.S. House Trading
No House trades found for GRNF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.